Retirement Systems of Alabama Sells 449 Shares of Charles River Laboratories International, Inc. $CRL

Retirement Systems of Alabama cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,539 shares of the medical research company’s stock after selling 449 shares during the quarter. Retirement Systems of Alabama’s holdings in Charles River Laboratories International were worth $1,599,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brooklyn Investment Group raised its holdings in Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC raised its holdings in Charles River Laboratories International by 542.9% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Charles River Laboratories International during the second quarter valued at about $56,000. Bayforest Capital Ltd bought a new stake in Charles River Laboratories International during the second quarter valued at about $63,000. Finally, Family Legacy Financial Solutions LLC bought a new stake in Charles River Laboratories International during the second quarter valued at about $71,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Down 5.5%

Shares of NYSE:CRL opened at $168.05 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The business has a 50 day simple moving average of $167.75 and a two-hundred day simple moving average of $154.44. The firm has a market capitalization of $8.27 billion, a PE ratio of -126.35, a price-to-earnings-growth ratio of 4.83 and a beta of 1.50. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.59 earnings per share. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on CRL. Wall Street Zen cut Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 23rd. Mizuho lifted their target price on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 17th. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their target price for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Finally, Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, October 3rd. Eight analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $181.29.

Insider Activity

In related news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).